Monday, 15 June 2026 07:45 AM
Company Update
OXFORD, UK / ACCESS Newswire / June 15, 2026 / Fine Treatment has highlighted increasing interest in non-invasive therapeutic approaches for the management of benign prostatic hyperplasia (BPH), a common age-related condition affecting millions of men worldwide. Growing awareness of treatment safety, quality-of-life considerations, and long-term symptom management continues to influence discussions surrounding enlarged prostate care.
Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland that commonly develops with age. The condition can contribute to urinary symptoms, including increased frequency of urination, difficulty initiating urination, weak urinary flow, nighttime urination, and incomplete bladder emptying. These symptoms often affect daily activities, sleep quality, and overall well-being.
How to treat and manage benign prostatic hyperplasia (BPH)?
Healthcare providers and patients continue to evaluate a range of treatment options, including lifestyle modifications, pharmaceutical therapies, surgical procedures, and non-invasive medical technologies. Recent developments within prostate health management have contributed to growing interest in approaches designed to reduce symptoms while minimizing treatment-related complications.
Among the areas receiving increased attention is Thermobalancing therapy, a non-invasive method that utilizes the body's natural heat to support prostate health. The therapy is delivered through Dr. Allen's Device, a wearable medical device developed for long-term home use.
The device incorporates a specially designed thermoelement positioned externally in the projection area of the prostate gland. The thermoelement accumulates body heat and maintains a constant temperature in the targeted area. The therapy is intended to support improved microcirculation and stable tissue conditions without the use of pharmaceuticals, invasive procedures, or external energy sources.
Choice of treatment method, risk assessment and patient preferences.
Interest in non-drug approaches has grown alongside ongoing discussions regarding the side effects associated with certain medications prescribed for BPH. Pharmaceutical therapies remain widely used; however, researchers continue to investigate potential adverse effects linked to long-term treatment.
Recent scientific studies have examined associations between specific classes of BPH medications and ocular health concerns. Research involving large patient populations has explored possible links between alpha-blocker use and an increased incidence of glaucoma, while other studies have reported various eye-related adverse effects associated with some medications used in prostate enlargement treatment.
These findings have contributed to broader conversations regarding treatment selection, risk assessment, and patient preferences. Healthcare professionals generally emphasize the importance of evaluating both potential benefits and risks when determining appropriate management strategies for benign prostatic hyperplasia.
As awareness of treatment alternatives expands, non-invasive solutions have become an area of growing interest among individuals seeking symptom relief without surgical intervention or medication-related side effects. Patient-centered care approaches increasingly focus on preserving quality of life, maintaining urinary function, and supporting overall well-being.
Fine Treatment advances new non-invasive medical technologies.
Dr. Allen's Device is manufactured and distributed by Fine Treatment, a company based in Oxford, United Kingdom. The device is classified as a Class I medical device and is available for home use. International distribution allows access to patients in multiple countries through tracked delivery services.
The broader prostate health landscape continues to evolve as healthcare providers, researchers, and patients examine a variety of treatment pathways. Advances in medical technology and growing interest in non-invasive therapeutic options are contributing to ongoing discussions regarding the future of benign prostatic hyperplasia management.
Fine Treatment noted that increased attention toward treatment safety, patient comfort, and long-term symptom management remains an important factor influencing interest in alternative approaches for enlarged prostate care.
About Fine Treatment
Fine Treatment is a United Kingdom-based company focused on the development and distribution of non-invasive medical devices. The company manufactures Dr. Allen's Device, a wearable medical technology designed to support Thermobalancing therapy for chronic diseases treatment, including prostate health management.
Company Details
Company Name: Fine Treatment
Contact Person: Alex Day
Email: [email protected]
Phone: +447958878300
Website: https://finetreatment.com/
SOURCE: Fine Treatment